ACTB pseudogene 8 (ACTBP8)

ACTB pseudogene 8 is a processed pseudogene related to the ACTB gene, which encodes the beta-actin protein central to cytoskeleton structure and cell motility[2][3]. Pseudogenes arise from reverse-transcribed RNA inserted into the genome, are typically characterized by sequence similarity to a parent gene, and generally lack coding potential due to mutations or truncations[4]. There is no evidence that ACTB pseudogene 8 produces a functional transcript or protein, nor does it have properties that would define it as a therapeutic or biological target. In general, ACTB pseudogenes are considered non-functional remnants and not targets for drug intervention. If structured target information is needed for drug discovery or therapeutic projects, ACTB pseudogene 8 should be treated as "not a valid target" for such purposes[4]. No evidence exists for a biological, pharmacological, or clinical role for ACTB pseudogene 8, and the use of the abbreviation "ACTBP2" for this locus is not standardized—databases vary in naming pseudogenes within the ACTB family. Researchers should cross-validate gene and pseudogene nomenclature using sources such as NCBI Gene, HGNC, and Ensembl. *Note:* If you are interested in **beta-actin** (protein-coding ACTB) rather than a pseudogene, this is a widely studied cytoskeletal protein involved in cell structure, motility, and various disease processes including cancer[2][3]. However, ACTB pseudogene 8 does not confer these functions.

Other names

ACTBP8ACTB pseudogene 8ACTBP2